Olema Pharmaceuticals Inc...
5.12
0.28 (5.79%)
At close: Jan 14, 2025, 3:59 PM
5.14
0.39%
Pre-market Jan 15, 2025, 08:31 AM EST
undefined%
Bid 5
Market Cap 380.13M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -2.28
PE Ratio (ttm) -2.25
Forward PE n/a
Analyst Buy
Ask 5.24
Volume 1,183,326
Avg. Volume (20D) 852,873
Open 5.44
Previous Close 4.84
Day's Range 4.78 - 5.44
52-Week Range 4.60 - 16.77
Beta undefined

About OLMA

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negativ...

Industry Biotechnology
Sector Healthcare
IPO Date Nov 19, 2020
Employees 74
Stock Exchange NASDAQ
Ticker Symbol OLMA

Analyst Forecast

According to 5 analyst ratings, the average rating for OLMA stock is "Buy." The 12-month stock price forecast is $27, which is an increase of 427.34% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts